Global Rheumatoid Arthritis Therapeutics (Biologics, Biosimilars, NSAIDs, Analgesics, DMARDs & Glucocorticoids) Market Outlook to 2025 - ResearchAndMarkets.com

The "Global
Rheumatoid Arthritis Therapeutics Market (By Type - Biologics,
Biosimilars, NSAIDs, Analgesics, DMARDs & Glucocorticoids; By Region -
North America, Europe & Asia Pacific) Market Outlook 2025"
report has been added to ResearchAndMarkets.com's
offering.

Global Rheumatoid Arthritis Therapeutics Market report provides an
in-depth analysis of global rheumatoid arthritis therapeutics market
across therapeutics segments such as Pharmaceuticals and
Biopharmaceuticals. Market outlook for rheumatoid arthritis therapeutics
market overall as well as across various sub-segments has been provided
for the period 2018-24. Regional analysis is done across major markets
in North America, Europe and the Asia Pacific.

Clinical diagnoses of rheumatoid arthritis have seen a turnaround with
the advent of multiple antibody assays such as antibodies to
citrullinated protein/peptide antigens (ACPAs). This helps in better
diagnosis and management of RA with much improved overall diagnostic
sensitivity. The market is also witnessing a shift towards combination
therapy which manifests results.

The report provides comprehensive coverage on major industry drivers,
restraints, and their impact on market growth during the forecast
period. Furthermore, the study encompasses various market-specific
growth opportunities in the global rheumatoid arthritis therapeutics
market.

Key Topics Covered:

1. Executive Summary

2. Research Methodology

3. Rheumatoid Arthritis

3.1 Overview

3.2 Causes

3.3 Types of RA

4. Rheumatoid Arthritis Diagnosis & Treatment

4.1 Diagnosis

4.2 Treatment

5. Market Analysis

5.1 Market Sizing (Actual & Forecasted)

5.2 Market Share Analysis

5.2.1 Market Share by Molecule Type

5.2.2 Market Share by Distribution Channel

5.2.3 Market Share by Region

6. Rheumatoid Arthritis Therapeutics

6.1 Biopharmaceuticals

6.1.1 Market Sizing (Actual & Forecasted)

6.1.2 Biologics

6.1.2.1 Market Sizing (Actual & Forecasted)

6.1.2.2 Market Share by Drug Type

6.1.3 Biosimilars

6.1.3.1 Market Sizing (Actual & Forecasted)

6.2 Pharmaceuticals

6.2.1 Market Sizing (Actual & Forecasted)

6.2.2 NSAIDs

6.2.3 Analgesics

6.2.4 DMARDs

6.2.4.1 Market Sizing (Actual & Forecasted)

6.2.5 Glucocorticoids

7. Regional Analysis

8. Market Dynamics

8.1 Industry Trends & Developments

8.1.1 Preference for Combination Therapies

8.1.2 Growing Demand for Janus Kinase (JAK) inhibitors

8.1.3 Use of Anti-ACPAs for Clinical Diagnosis

8.1.4 FDA Approval of Auto-Injector for RA

8.2 Growth Drivers

8.2.1 Prevalence of Rheumatoid Arthritis

8.2.2 Increasing Geriatric Population

8.2.3 Growing Patient Awareness

8.3 Challenges

8.3.1 Entry of Biosimilars

8.3.2 High Cost of Treatment

8.3.3 Issues related to Insurance & Reimbursement

9. Competitive Landscape

10. Company Profiles

• Abbvie Inc
• Amgen Inc
• F. Hoffman - La Roche AG
• Johnson & Johnson
• Pfizer Inc

For more information about this report visit https://www.researchandmarkets.com/research/kstjd5/global_rheumatoid?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190124005434/en/